Current evidence from monogenic Parkinson's disease (PD) supports the view that PD is a clinical syndrome, rather than a single disease entity, and that the heterogeneity of PD indeed reflects different pathogenesis. Recent developments in functional imaging have enabled the in vivo assessment of cellular and molecular pathology of PD with respect to temporal and topographical patterns. We propose that this new technology will be useful for linking monogenic and sporadic PD, and thus, for classifying PD based on the pathogenesis. It will be also useful in clinico-genetic studies exploring susceptibility factors and at-risk groups, which are important for neuroprotective treatment when it becomes available. J Clin Neurol 2(2): [83][84][85][86][87][88][89][90][91] 2006 
INTRODUCTION
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) visualize and estimate quantitatively metabolic, biochemical or functional activities in a living brain; hence, called as functional imaging. Since SPECT and PET were first introduced in Korea in 1986 and 1994 respectively, technical advances and availability have grown at a remarkable pace. As of 2005, there are 187 SPECT cameras, 54 PET or PET/CT, 4 microPET, and 15 cyclotrons (which produce radiolabeled tracers) across the country; moreover, SPECT/CT fusion and highresolution research tomograph (HRRT) will be introduced. In the future, it may be possible to see highresolution Compton gamma camera and PET/MR fusion made in Korea. There is no doubt that the rapid expansion of this infrastructure will contribute enormously to efforts of neuroscience community searching for prevention or curative treatment of neurodegenerative disorders -the last frontier of medicine.
The goal of this review is to discuss the current issues on Parkinson's disease (PD), and establish the rationale for using this relatively new technology in clinical research and practice for PD.
DEFINITION OF PARKINSON'S DISEASE
In 1817 at the start of the Industrial Revolution, James Parkinson first reported PD in his monograph, The diagnosis of PD has been based on clinical and pathological features. UK PD Society Brain Bank clinical diagnostic criteria (one of most stringent criteria, widely used for research purposes; also known as QSBB criteria) consist of three steps: (1) diagnosis of parkinsonian syndrome; (2) exclusion of atypical features including significant family history and early severe dementia; (3) supportive prospective positive criteria observed during the longitudinal evaluation. 3 The clinical diagnosis of PD is confirmed by postmortem pathological examinations with loss of pigmented neurons and the presence of Lewy bodies in the substantia nigra. Based on these criteria, 76% of clinically diagnosed PD was confirmed pathologically. 4 This traditional way of defining PD is challenged by mounting new information derived from studies in familial PD.
CHANGING CONCEPT: PD AS A CLINICAL SYNDROME
Since the first report of a familial PD with mutations in α -synuclein gene in 1997, at least five more genes have been identified as a causative mutation in familial PD (Table 1) . 5 Subsequent clinical and pathological studies of affected people in these families revealed unexpected findings. First, patients with leucine-rich repeat kinase 2 (LRRK2) mutation showed pleomorphic pathology even within a family: Lewy bodies, tauopathy or neuronal loss without intracellular inclusions. 6, 7 Patients with parkin mutations showed dopamine neuronal loss without intracellular inclusions and/or tauopathy in most cases, and Lewy bodies in some with heterozygous mutation. 8 Interestingly, previous pathological studies in clinically diagnosed sporadic PD also reported a few cases showing neuronal loss without intracellular inclusions 9 or tauopathy. 10 Second, clinical phenotypes and pathological features ranged from typical idiopathic PD to diffuse Lewy body disease between individuals with mutation in the same gene, encoding LRRK2 7 or α -synuclein multiplication. 11 Third, seemingly sporadic PD might in fact have a genetic basis, blurring the boundary between sporadic and familial PD. [12] [13] [14] Therefore, significant family history should not exclude the diagnosis of PD, 15 as in the current QSBB criteria. These observations also indicate that the presence of Lewy bodies in the postmortem brain cannot be used to "confirm" the disease 16 because the pathology of PD is likely an outcome of disease process, i.e. phenotype, rather than a determining factor of the disease.
NEW APPROACH TO PD: A NEED FOR PATHOGENIC CLASSIFICATION
Traditional belief that PD is a relatively homogeneous disease entity, which can be separated from other similar disorders by applying stringent diagnostic criteria, has crumbled. Now, we have definite evidence for the longstanding argument that PD is a clinical syndrome. 17, 18 More than 100 years ago, Charcot changed the name of this disorder, "shaking palsy" that is a syndromic description, to "Parkinson's disease" that implies a homogeneous entity as a disease. After all, this revised term is turned out to be a misnomer again.
What is the impact of these new developments in everyday practice? Perhaps, the most compelling issue is whether the diagnosis of PD will be good enough for the treatment of disorder. Will this syndromic diagnosis guide us to tell patients the prognosis and definite treatment? From the clinician's viewpoint, it is most useful if a disease is defined and classified based on the pathogenesis. By analogy, the diagnosis of pneumonia is not sufficient for the treatment. The physician should understand the underlying pathogenic process, e.g. infection, autoimmune or aspiration. Then, is it possible to categorize idiopathic sporadic PD based on pathogenesis?
The study of genetics has been successful in identifying key proteins and causative mutations in familial PD. It will continue to make headway in elucidating molecular pathogenesis of familial PD. However, monogenic PD explains only 20% of the early onset PD and less than 3% of the late onset PD. 19 The rest are all sporadic and idiopathic PD. Can we then relate findings in familial PD to sporadic PD? Clinical phenotypes of familial PD, if all subtypes are lumped together, are as heterogeneous as those of sporadic PD. However, it is relatively homogeneous in each subtype of familial PD. The clinical phenotypes of dominant parkinsonism, especially Park8, are largely indistinguishable from typical late-onset idiopathic PD. The phenotype of Park1 is an aggressive doparesponsive parkinsonism with earlier onset (mean age of 46.5 years) and more rapid progression, compared with typical idiopathic PD. 20 It also shows a gene-dose effect on clinical and pathological phenotypes, more extensive with greater multiplication of α -synuclein gene. In contrast, the clinical phenotype of recessive parkinsonism (e.g. Park2, Park6 and Park7 with mutations in parkin, PTEN-induced putative kinase 1 (PINK1) and DJ-1 respectively) is typically a young-onset PD (YOPD, the onset between 20~40 years of age) with slow progression and good response to L-dopa. This triad of recessive genes is variably associated with mitochondria, and protective against mitochondrial dysfunction and oxidative stress. 24, 25 Although the pathological data are not available to all subtypes, at least, Park2 shows neuronal loss generally without protein aggregation, distinct from mutations in dominant genes that produce protein aggregation pathology. 25 Therefore, while different gene mutations are associated with different pathogenic mechanisms and different clinical and pathological phenotypes, those with similar pathogenic mechanisms tend to show similar clinical phenotype (Fig. 1) . If one accepts the argument that the pathogenic mechanism is a major factor determining clinical and pathological phenotypes, one may assume that the pathogenic mechanism of a subtype of sporadic PD would be similar to that of familial PD with similar clinical and pathological phenotypes. It has been thought that heterogeneity in sporadic idiopathic PD may suggest the existence of subgroups within the disorder, with distinct clinical patterns and perhaps different pathogenic mechanisms. 26 However, without a specific biologic marker or a test, the subtyping of sporadic PD has been entirely dependant on clinical features: specific motor symptoms (tremor predominant vs. postural instability and gait difficulty, PIGD), age at onset (young-onset vs. old-onset), accompanying dementia, or data-driven approach without a priori assumption. 27, 28 Fifteen years ago, Graham et al reported interesting findings in their data-driven approach, which are relevant to the current observations in familial PD. They could identity 3 distinctive subtypes in sporadic PD: the "motor only", "motor and cognitive", and "rapid progression". 27 The "motor only" subtype could correspond to benign YOPD in most recessive parkinsonism, whereas the "motor and cognitive" and the "rapid progression" could correspond to Park8 and Park1 (with duplication or triplication) respectively. This example demonstrates that a parallelism may indeed exist between sporadic and familial PD with respect to the disease phenotype. Recently, new application of PET and SPECT for exploring biochemical and pathological aspects of disease, [29] [30] [31] which will be discussed in the following sections, makes it possible to test this hypothesis by providing necessary biomarkers for sporadic PD (Fig. 2) .
CURRENT STATE OF FUNCTIONAL IMAGING FOR FAMILIAL PD
In recent years, PET and SPECT have been increasingly used for studies on familial PD. F]-FP-CIT binding in the striatum with significant rostrocaudal gradient in a patient with homozygous mutation, but mild reduction only, without significant rostrocaudal gradient in asymptomatic sister with homozygous mutation. 38 Mutations in the LRRK2 gene cause autosomal dominant parkinsonism that is clinically and pathologically indistinguishable from typical late-onset, sporadic idiopathic PD. 7, 39 Moreover, the disease penetrance in LRRK2 carriers is age-dependent, increasing from 17% at age 50 years to 85% at age 70 years, 40 simulating the age-dependent increase of sporadic idiopathic PD. [
18 F]-dopa PET in two patients with LRRK2 mutation did not show significant differences from idiopathic PD. 41 The collaborative study between people in Vancouver and Mayo Jacksonville, using three presynaptic tracers of [ ]-ioflupane SPECT study in 10 Italian patients with LRRK2 mutation (7 familial, 3 sporadic) also did not show significant differences between PD with LRRK2 mutation and without mutation. 43 
FUTURE PROSPECTS: PATHOLOGICAL IMAGING
Functional imaging in familial PD has been conducted using only dopamine tracers. Heterogeneity of familial and sporadic PD is, however, largely accounted for by non-dopamine and Alzheimer pathology; thus, PET or SPECT with multiple tracers can explore the extent of chemical or morphological pathology in the brain. There are three potentially useful tracers, which are in line with our interests.
The first tracer is a cholinergic ligand. Dementia is the most important variable in the categorization of PD, and attributed to multiple mechanisms including cortical cholinergic deficits, [44] [45] [46] Alzheimer pathology and cortical
Lewy pathology in addition to dopamine or other monoamine deficits.
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C-labeled acetylcholine analog is a presynaptic marker, measuring the activity of acetylcholine esterase in the cortex (which reflects cholinergic terminal density). There are two types: [ 60 Since PBBS expresses in activated microglia, it began to be used for neurodegenerative disorders after McGeer reported abundant activated microglia in the PD and AD brains. 61, 62 This tracer is potentially important because microglial response may be used as a marker for disease activity in PD, which is otherwise not available. Therefore, in principle, it may localize the area of brain where the disease process is active, and also may show the time course of disease activity in a given region -findings which would be highly meaningful for the study of putative neuroprotective agents. In 2005, Ouchi et al first reported a study in PD patients, using two tracers of [ In summary, with a variety of tracers that can provide biochemical and molecular aspects of pathology, we are now in a position to explore longitudinal changes of pathology in PD patients. The "functional" imaging is evolving into the "pathological" imaging; thus, for the first time since James Parkinson's clinical report, it becomes a reality to combine the two major expressions of disease, i.e. clinical and pathological phenotypes, in real time.
CONCLUSIONS
Throughout the history, advances in scientific technology have led to new discoveries and innovative treatments in medicine. With a rapid development of computed imaging device and radiopharmaceuticals, we are now facing a new opportunity for PD, almost 200 years after first reported. Functional imaging will make it possible to categorize PD into subtypes with distinct pathogenesis. It will be also instrumental for clinicogenetic studies identifying susceptibility factors and at-risk groups, which are essential for successful neuroprotective treatment when it becomes available.
